Skip to main content
KISSEI PHARMACEUTICAL CO.,LTD. logo

KISSEI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4547 ISIN · JP3240600001 T Manufacturing
Open in API
Filings indexed 82 across all filing types
Latest filing 2026-06-03 Transaction in Own Shar…
Country JP Japan
Listing T 4547

About KISSEI PHARMACEUTICAL CO.,LTD.

https://www.kissei.co.jp/e_contents/

Kissei Pharmaceutical Co., Ltd. is a research-driven company engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The company concentrates its research and development investments in key therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its broader product portfolio also addresses conditions in metabolic and endocrinological, obstetrics and gynecological, and ophthalmic fields. Committed to creating innovative medicines, Kissei aims to contribute to global health by addressing unmet medical needs. The company also operates in the health foods sector.

Recent filings

Filing Released Lang Actions
Notice Concerning Status of Acquisition of Treasury Shares
Transaction in Own Shares Classification · 95% confidence The document is an announcement by KISSEI PHARMACEUTICAL CO., LTD. describing the status of its acquisition of treasury shares, including number of shares acquired, total amount, acquisition period, and methods, as well as reference to the board resolution authorizing the buyback. This exactly matches the definition for “Transaction in Own Shares (POS),” which covers reports of a company buying back its own shares.
2026-06-03 English
自己株式の取得状況に関するお知らせ
Transaction in Own Shares Classification · 93% confidence The document is a Japanese-language notice by Kissei Pharmaceutical (code 4547) detailing the status of its treasury stock acquisitions under the Companies Act, including the board resolution parameters and the zero shares actually acquired in the period. This is a report of the company’s share repurchase activity (transaction in its own shares). Under the defined categories, this fits the “Transaction in Own Shares” classification (Code: POS).
2026-06-03 Japanese
急性骨髄性白血病治療薬オルタシデニブの国内製造販売承認申請のお知らせ
Regulatory Filings Classification · 85% confidence The document is a press release by a pharmaceutical company announcing that it has submitted a domestic manufacturing and marketing approval application for a drug to Japanese regulators. There are no financial results, director changes, share transactions, or detailed investor presentation materials. This is a general regulatory announcement about a drug approval submission, which falls under the fallback category Regulatory Filings (RNS).
2026-05-27 Japanese
タブネオスの安全性確保のための注意喚起について
Regulatory Filings Classification · 75% confidence The document is a corporate press release notifying a safety alert (‘ブルーレター’) and label revision for a pharmaceutical product by the company, with no financial statements, no shareholder votes, no management changes, nor proxy or dividend information. It is a regulatory compliance announcement regarding drug safety. This falls under the general regulatory announcements/fallback category.
2026-05-21 Japanese
2026年3月期 決算説明会資料
Investor Presentation Classification · 90% confidence The document is a 2026年3月期 決算説明会 (‘financial results presentation’) slide deck by the company president, containing detailed performance summaries, segment results, pipeline updates, and future outlook. It clearly serves as an investor presentation rather than a concise earnings release or statutory annual report. This matches the definition of an Investor Presentation (Code: IP).
2026-05-12 Japanese
自己株式の取得及び自己株式の消却に関するお知らせ
Transaction in Own Shares Classification · 90% confidence The document is a formal announcement by Kisai Pharmaceutical Co., Ltd. regarding the Board resolution to acquire (buy back) up to 1,300,000 shares of its own common stock and subsequently cancel those treasury shares under Companies Act provisions. This clearly describes a share repurchase and cancellation (transaction in own shares). It is not a financing update, governance notice, or dividend; it matches the definition of “Transaction in Own Shares.”
2026-05-11 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.